Public Citizen recently called on the U.S. Food and Drug Administration (FDA) to take certain steps that would both prohibit the practice of advisory committee members simultaneously serving as paid speakers on behalf of drug or pharmaceutical companies and impose a “cooling-off period” between service as a committee voting member and the performance of “speaking or consulting roles on behalf of a sponsor before any future committee meeting.” The organization also called for amendments to the agency’s 2008 advisory committee conflict-of-interest guidance to disqualify from participation in an upcoming committee meeting those whose previous paid speaking or consulting arrangement on behalf of a sponsor at an FDA advisory committee occurred “within a reasonably recent period of time.” Public Citizen is concerned that such “revolvingdoor arrangements . . . undermine public confidence in FDA advisory committees and in the agency itself,” particularly where these committees evaluate drug or medical device risks and benefits.